Methods and compounds for inhibiting amyloid deposits

Details Methods and compounds for inhibiting amyloid deposits Methods and compounds for inhibiting amyloid deposits

2003-05-02

2008-07-01

Wang, Shengjun (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C514S866000

Reexamination Certificate

active

07393875

ABSTRACT:
Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.

REFERENCES:
patent: 3872125 (1975-03-01), Houlihan et al.
patent: 4199601 (1980-04-01), Durlach
patent: 4267194 (1981-05-01), Durlach
patent: 4271189 (1981-06-01), Durlach
patent: 4355043 (1982-10-01), Durlach
patent: 4386081 (1983-05-01), Helgstrand et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4540564 (1985-09-01), Bodor
patent: 4563470 (1986-01-01), Durlach
patent: 4591583 (1986-05-01), Helgstrand et al.
patent: 5164295 (1992-11-01), Kisilevsky et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5194654 (1993-03-01), Hostetler et al.
patent: 5236910 (1993-08-01), Egidio et al.
patent: 5242932 (1993-09-01), Gandy et al.
patent: 5276059 (1994-01-01), Caughey et al.
patent: 5374548 (1994-12-01), Caras
patent: 5385915 (1995-01-01), Buxbaum et al.
patent: 5389623 (1995-02-01), Bodor
patent: 5399331 (1995-03-01), Loughrey et al.
patent: 5416016 (1995-05-01), Low et al.
patent: 5463092 (1995-10-01), Hostetler et al.
patent: 5576419 (1996-11-01), Fields
patent: 5643562 (1997-07-01), Kisilevsky et al.
patent: 5728375 (1998-03-01), Kisilevsky et al.
patent: 5840294 (1998-11-01), Kisilevsky et al.
patent: 5858326 (1999-01-01), Kisilevsky et al.
patent: 5869469 (1999-02-01), Szarek et al.
patent: 5952389 (1999-09-01), Fogel
patent: 5972328 (1999-10-01), Kisilevsky et al.
patent: 6037327 (2000-03-01), Castillo et al.
patent: 6310073 (2001-10-01), Kisilevsky et al.
patent: 6562836 (2003-05-01), Szarek et al.
patent: 2031433 (1991-06-01), None
patent: 2046037 (1992-01-01), None
patent: 4313118 (1994-10-01), None
patent: 003275 (1981-09-01), None
patent: 115657 (1984-08-01), None
patent: 236251 (1987-09-01), None
patent: 0434173 (1991-06-01), None
patent: 0464759 (1992-01-01), None
patent: 797992 (1997-10-01), None
patent: WO-92/14456 (1992-09-01), None
patent: WO-94/22437 (1994-10-01), None
patent: WO-94/27602 (1994-12-01), None
patent: WO-95/06477 (1995-03-01), None
patent: WO-96/28187 (1996-09-01), None
patent: WO-97/07402 (1996-09-01), None
patent: WO-96/37612 (1996-11-01), None
patent: WO-97/09976 (1997-03-01), None
patent: WO-97/16191 (1997-05-01), None
patent: WO-98/11923 (1998-03-01), None
patent: WO-98/13046 (1998-04-01), None
patent: WO-98/25938 (1998-06-01), None
patent: WO-00/06133 (2000-02-01), None
patent: WO-00/57707 (2000-10-01), None
patent: WO-00/64420 (2000-11-01), None
patent: WO-01/03680 (2001-01-01), None
Johnson et al., Newly Identified Pancreatic Protein Islet Amyloid Polypeptide, What Is Its Relationship to Diabetes?, (1991) Diabetes, vol. 40, pp. 310-314).
Berge, Stephen M. et al., “Pharmaceutical Salts,”Journal of Pharmaceutical Sciences, vol. 66(1):1-19 (1977).
Bloemen, P.G.. et al. “Adhesion molecules: a new target for immunoliposome-mediated drug delivery.”FEBS Lett., 1995; 357(2):140-4.
Briscoe, P., et al. “Delivery of superoxide dismutase to pulmonary epithelium via pH-sensitive liposomes.”Am. J. Physiol.1995; 268:L374-80.
Copani, A., et al. “Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-am7yloid peptide.”Mol. Pharm.1995; 47(5):890-89.
Hutchings, R., et al. “The effect of excitotoxin antagonists on ibotenic and acid-induced alteration of app Mma hippocampal expression.”J. Pharmacy and Pharmacology. 1995; 47(12B):1131.
Keinanen, K., et al. “Biosynthetic lipid-tagging of antibodies.”FEBS Lett.1994; 346(1):123-6.
McCubbin, et al. “Circular-dichroism studies on two murine serum amyloid A proteins.”Biochem J. 1988; 256:775-83.
Killion, J.J., et al. “Systemic targeting of liposome-encapsulated immunomodulators to macrophages for treatment of cancer metastasis.”Immunomethods. 1994; 4(3):273-9.
Morgan, et al. “Approaches to the discovery of non-peptide ligands for peptide receptors and peptidases.”Ann. Rep. Med. Chem.1989; 243-53.
Noren, J.O., et al. “Synthesis of esters of phosphonoformic acid and their antiherpes activity.”J. Med. Chem.1983; 26(2):264-70.
Owais, M., et al. “Chloroquine encapsulated in malaria-infected erythrocyte-specific antibody-bearing liposomes effectively controls chloroquine-resistantPlasmodium bergheiinfections in mice.”Antimicrob Agents Chemother.1995; 39(1):180-4.
Puchtler, et al. “Application of Thiazole Dyes to Amyloid Under Conditions of Direct Cotton Dyeing: Correlation of HIstochemical and Chemical Data.”Histochemistry. 1983; 77:431-45.
Ranade, V.V. “Drug delivery systems. 1. site-specific drug delivery using liposomes as carriers.”J. Clin. Pharmacol.1989; 29(8):685-94.
Schreier, H., et al. “Targeting of liposomes to cells expressing CD4 using glycosylphosphatidylinositol-anchored gp120. Influence of liposome composition on intracellular trafficking,”J. Biol. Chem.1994; 269(12):9090-98.
Small, et al. “Association and Release of the Amyloid Protein Precursor of Alzheimer's Disease from Chick Brain Extracellular Matrix.”J. Neuroscience.1992; 12:4143-50.
Strejan, G.H., et al. “Suppression of chronic-relapsing experimental allergic encephalomyelitis in strain-13 guinea pigs by administration of liposome-associated myelin basic protein.”J. Neuroimmunol.1984; 7(1):27-41.
Umezawa, et al., “Liposome targeting to mouse brain: mannose as a recognition marker.”Biochem. Biophys. Res. Commun.1988; 153(3):1038-44.
Aprile, C., et al. “Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin.”Eur. J. Nucl. Med.,1995; 22(12):1393-1401.
Axelrad, et al. “Further Characterization of Amyloid Enhancing Factor.”Laboratory Investigation.1982; 47:139-146.
Baures, P.W., et al. “Discovering transthyretin amyloid fibril inhibitors by limited screening.”Bioorg Med Chem.Aug. 1998; 6(8):1389-401.
Boismare, F., et al. “A Homotaurine Derivative Reduces the Voluntary Intake of Ethanol by Rats: are Cerebral GABA Receptors Involved?”Pharmacology Biochemistry&Behavior. 1984; 21:787-789.
Briggs, A.D., et al. “Acyloxymethyl and 4-acyloxybenzyl diester prodrugs of phosphonoformate.”Tetrahedron, 1996; 52(47):14937-50.
Brissette, et al. “Differential Induction of the Serum Amyloid A Gene Family in Response to an Inflammatory Agent and to Amyloid-enhancing Factor.”The Journal of Biological Chemistry.1989; 264(32):19327-32.
Campagna, F., et al. “Cyclic Amidine Analogues Of Taurine And Homotaurine: Systhesis And Effects On Rats Skeletal Muscle.”II Farmaco.1994; 49(10): 653-8.
Caughey, B., et al. “Sulfated Polyanion Inhibition of Scrapie-Associated PrP Accumulation in Cultured Cells.”Journal of Virology.1993; 67(2):643-650.
Caughey, B. “Scrapie-Associated PrP Accumulation and Its Prevention: Insights from Cell Culture.”Brit. Med. Bull.1993; 49:860-72.
Caughey, B. “Protease-resistant PrP accumulation and scrapie agent replication: a role for sulphated glycosaminoglycans?”,Biochem. Soc. Trans.1994; 22:163-7.
Caughey, B. “Scrapie-associated PrP accumulation and agent replication: effects of sulphated glycosaminoglycan analogues.”Phil. Trans. R. Soc. Lond. B.1994; 343:399-404.
Caughey, B., et al. “Binding of the Protease-Sensitive Form of Prion Protein PrP to Sulfated Glysocaminoglycan and Congo Red.”Journal of Virology. 1994; 68:2135-

Affiliated with

Also associated with

Rating

Methods and compounds for inhibiting amyloid deposits does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compounds for inhibiting amyloid deposits, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compounds for inhibiting amyloid deposits will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3963501